IN8bio (NASDAQ:INAB) versus Anavex Life Sciences (NASDAQ:AVXL) Head-To-Head Review

Anavex Life Sciences (NASDAQ:AVXLGet Free Report) and IN8bio (NASDAQ:INABGet Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, earnings, dividends and risk.

Insider & Institutional Ownership

31.6% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 92.1% of IN8bio shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 15.5% of IN8bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Volatility & Risk

Anavex Life Sciences has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500. Comparatively, IN8bio has a beta of 0.14, indicating that its share price is 86% less volatile than the S&P 500.

Profitability

This table compares Anavex Life Sciences and IN8bio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -29.04% -26.85%
IN8bio N/A -151.40% -107.81%

Earnings and Valuation

This table compares Anavex Life Sciences and IN8bio’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Anavex Life Sciences N/A N/A -$47.51 million ($0.50) -7.58
IN8bio N/A N/A -$30.01 million ($0.91) -1.44

Anavex Life Sciences is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Anavex Life Sciences and IN8bio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences 0 0 1 0 3.00
IN8bio 0 0 2 0 3.00

Anavex Life Sciences currently has a consensus target price of $40.00, indicating a potential upside of 955.41%. IN8bio has a consensus target price of $10.00, indicating a potential upside of 663.36%. Given Anavex Life Sciences’ higher possible upside, research analysts plainly believe Anavex Life Sciences is more favorable than IN8bio.

About Anavex Life Sciences

(Get Free Report)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.

About IN8bio

(Get Free Report)

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.